Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19

• المؤلفون الرئيسيون: Thomas J. Esparza (مؤلف), Yaozong Chen (مؤلف), Negin P. Martin (مؤلف), Helle Bielefeldt-Ohmann (مؤلف), Richard A. Bowen (مؤلف), William D. Tolbert (مؤلف), Marzena Pazgier (مؤلف), David L. Brody (مؤلف)
• التنسيق: كتاب
• منشور في: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

There remains an unmet need for globally deployable, low-cost therapeutics for the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Previously, we reported on the isolation and in vitro characterization of a potent single-domain nanobody, NIH-CoVnb-112, specific for the...